Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma

Current Signal Transduction Therapy

Volumn 8, Issue 3, 2013, Pages 210-218

  Kornakiewicz, Anna ^a,b,c   Solarek, Wojciech ^a,b   Bielecka, Zofia F ^a,b   Lian, Fei ^d   Szczylik, Cezary ^a   Czarnecka, Anna M ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Collegium Invisibile ^*  (Poland)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti angiogenic therapy; Cancer stem cells; Clear cell renal cell carcinoma; Drug resistance; Dual mTOR inhibitors; Everolimus; Temsirolimus; Tumor microenvironment

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SURVIVIN; TEMSIROLIMUS;

ANGIOGENESIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; DRUG SENSITIVITY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; KIDNEY CARCINOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84900542473     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574362409666140206222746     Document Type: Article

References (73)

1. Gamelin E, Mertins SD, Regis JT, Mickley L, Abati A, Worrell RA, et al. Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol. 1999 Jul; 162(1): 217-24.
2. Jonasch E, Futreal A, Davis I, Bailey S, Kim WY, Brugarolas J, et al. State-of-the-science: An update on renal cell carcinoma. Mol Cancer Res. 2012 Jul; 10(7): 859-80.
3. Dorević G, Matusan-Ilijas K, Babarović E, Hadzisejdić I, Grahovac M, Grahovac B, et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res CR. 2009; 28: 40.
4. Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C, et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol. 1997 Apr; 157(4): 1482- 6. (Pubitemid 27130856
5. Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008 Aug; 19(8): 1470-6.
6. Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer Oxf Engl 1990. 2010 Sep; 46(13): 2432-40.
7. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012 Apr 1; 118(7): 1868-76.
8. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer Oxf Engl 1990. 2013 Apr; 49(6): 1287-96.
9. Taneja SS. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. J Urol. 2012 Aug; 188(2): 412-3.
10. Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf. 2012 Sep; 11(5): 861-79.
11. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15; 116(18): 4256-65.
12. Posadas EM, Limvorasak S, Sharma S, Figlin RA. Targeting angiogenesis in renal cell carcinoma. Expert Opin Pharmacother. 2013 Nov; 14(16): 2221-36.
13. Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant. 2012 Oct 24; 2(5): 74- 83.
14. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 4; 499(7456): 43-9.
15. Venugopal B, Ansari J, Aitchison M, Tho LM, Campbell R, Jones RJ. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol. 2013; 13: 26.
16. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit Rev Oncol Hematol. 2012 Jun; 82(3): 323-37.
17. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31; 356(22): 2271-81.
18. Wang Y. Everolimus in renal cell carcinoma. Drugs Today Barc Spain 1998. 2010 Aug; 46(8): 557-66.
19. Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011 Jul; 8(4): 359-67.
20. Jiang B-H, Liu L-Z. Role of mTOR in anticancer drug resistance. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2008 Jun; 11(3): 63-76.
21. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009 Oct 15; 122(20): 3589-94.
22. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006 Feb; 7(2): 85-96.
23. Wang L, Rhodes CJ, Lawrence JC. Activation of Mammalian Target of Rapamycin (mTOR) by Insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1. J Biol Chem. 2006 Aug 25; 281(34): 24293-303.
24. Carrière A, Cargnello M, Julien L-A, Gao H, Bonneil E, Thibault P, et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol CB. 2008 Sep 9; 18(17): 1269-77.
25. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003 Jul; 17(7): 1263-93.
26. Inoki K, Li Y, Zhu T, Wu J, Guan K-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002 Sep; 4(9): 648-57.
27. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005 Apr 22; 121(2): 179-93.
28. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008 Jun 1; 412(2): 179-90.
29. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol CB. 2005 Apr 26; 15(8): 702-13.
30. Wang L, Harris T. E, Roth R. A, Lawrence J. C. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding, J. Biol. Chem., 2007 July; t. 282, nr 27, ss. 20036-20044.
31. Khaleghpour K, Pyronnet S, Gingras A-C, Sonenberg N. Translational Homeostasis: Eukaryotic Translation Initiation Factor 4E Control of 4E-Binding Protein 1 and p70 S6 Kinase Activities. Mol Cell Biol. 1999 Jun; 19(6): 4302-10.
32. Choo AY, Yoon S-O, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-typespecific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008 Nov 11; 105(45): 17414-9.
33. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009 Oct; 10(10): 992-1000.
34. Kucejova B, Pena-Llopis S, Yamasaki T, Sivanand S, Tran TAT, Alexander S, et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res MCR. 2011 Sep; 9(9): 1255-65.
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex. Science. 2005 Feb 18; 307(5712): 1098-101.
36. Shanmugasundaram K, Block K, Nayak BK, Livi CB, Venkatachalam MA, Sudarshan S. PI3K regulation of the SKP- 2/p27 axis through mTORC2. Oncogene. 2013 Apr 18; 32(16): 2027-36.
37. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008 Sep; 118(9): 3065-74.
38. Veilleux A, Houde VP, Bellmann K, Marette A. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3- L1 adipocytes. Mol Endocrinol Baltim Md. 2010 Apr; 24(4): 766- 78.
39. Zhao Y, Ehara H, Akao Y, Shamoto M, Nakagawa Y, Banno Y, et al. Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun. 2000 Nov 11; 278(1): 140-3.
40. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009 Mar; 29(6): 1411-20.
41. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006 Mar; 26(6): 2019-28.
42. Wang K, Li Z, Chen Y, Su C. The pharmacokinetics of a novel anti-tumor agent, beta-elemene, in Sprague-Dawley rats. Biopharm Drug Dispos. 2005 Oct; 26(7): 301-7.
43. Zhan Y-H, Liu J, Qu X-J, Hou K-Z, Wang K-F, Liu Y-P, et al. β- Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways. Asian Pac J Cancer Prev APJCP. 2012; 13(6): 2739-44.
44. Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012 Jun; 8(6): 903-14.
45. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1. J Biol Chem. 2009 Mar 20; 284(12): 8023-32.
46. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008 Dec 12; 283(50): 34495-9.
47. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008 Dec 9; 14(6): 435-46.
48. Harada K, Miyake H, Kumano M, Fujisawa M. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer. 2013 Oct 29; 109(9): 2389-95.
49. Tabatabaian F, Dougherty K, Di Fulvio M, Gomez-Cambronero J. Mammalian target of rapamycin (mTOR) and S6 kinase downregulate phospholipase D2 basal expression and function. J Biol Chem. 2010 Jun 18; 285(25): 18991-9001.
50. Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res Off J Am Assoc Cancer Res. 2010 Jan 1; 16(1): 141-53.
51. Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T. A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol. 2013 Oct; 43(4): 1080-6.
52. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013 Aug; 45(8): 860-7.
53. Garcia-Donas J, Rodriguez-Antona C, Jonasch E. Molecular markers to predict response to therapy. Semin Oncol. 2013 Aug; 40(4): 444-58.
54. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010 May; 7(5): 277-85.
55. Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang C-H. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer. 2013 Apr 1; 13: 170.
56. Yuen JSP, Cockman ME, Sullivan M, Protheroe A, Turner GDH, Roberts IS, et al. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene. 2007 Oct 4; 26(45): 6499-508.
57. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012 Feb 14; 21(2): 227-39.
58. Calnan DR, Brunet A. The FoxO code. Oncogene. 2008 Apr 7; 27(16): 2276-88.
59. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007 Oct; 8(10): 774-85.
60. Inoki K, Zhu T, Guan K-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003 Nov 26; 115(5): 577-90.
61. Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol. 2012; 2012: 281261.
62. Sakamoto T, Weng JS, Hara T, Yoshino S, Kozuka-Hata H, Oyama M, et al. HIF-1 regulation through crosstalk between mTOR and MT1-MMP. Mol Cell Biol. 2013 Oct 28;
63. Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin RA, et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PloS One. 2013; 8(1): e54918.
64. Gil J, Stembalska A, Pesz KA, Sasiadek MM. Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet. 2008; 49(2): 193-9.
65. Ochocki JD, Simon MC. Nutrient-sensing pathways and metabolic regulation in stem cells. J Cell Biol. 2013 Oct 14; 203(1): 23-33.
66. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013; 4: e875.
67. Yang C, Peng J, Jiang W, Zhang Y, Chen X, Wu X, et al. mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo. Cancer Lett. 2013 Aug 7.
68. Cai Z, Ke J, He X, Yuan R, Chen Y, Wu X, et al. Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer. Ann Surg Oncol. 2013 Aug 2.
69. Axelson H, Johansson ME. Renal stem cells and their implications for kidney cancer. Semin Cancer Biol. 2013 Feb; 23(1): 56-61.
70. Huang B, Huang YJ, Yao ZJ, Chen X, Guo SJ, Mao XP, et al. Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PloS One. 2013; 8(7): e68293.
71. Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer J Int Cancer. 2013 Aug 15; 133(4): 788-96.
72. Cho DC, Mier JW. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets. 2013 Feb; 13(2): 126-42.
73. Li H, Jin X, Zhang Z, Xing Y, Kong X. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Cell Biochem Funct. 2013 Jul; 31(5): 427-33.